BCL2 and pancreatic neoplasm: It has previously shown that Bcl-2 confers resistance to gemcitabine-induced apoptosis in pancreatic cancer cells, and siRNA-mediated silencing of anti-apoptotic Bcl-2 enhances chemotherapy sensitivity in human pancreatic cancer cells in vitro and might lead to improved therapy responses in advanced stages of this disease [13].